Please login to the form below

Not currently logged in
Email:
Password:

Relypsa

This page shows the latest Relypsa news and features for those working in and with pharma, biotech and healthcare.

Vifor wins European approval for Veltassa

Vifor wins European approval for Veltassa

The go-ahead is a significant milestone for Vifor Pharma Group - who acquired Veltassa from Relypsa - as it marks the drug’s first regulatory approval outside the US. ... Relypsa plans to submit Veltassa applications in other markets worldwide and the

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    Veltassa was approved in late 2015 and Relypsa achieved revenues of $30.9m since its launch, making the 50x revenue multiple paid look relatively attractive. ... Licence, co-development, equity stake. 2, 561. Relypsa/ Galenica. Veltassa - Potassium binder

  • Pharma deals in August 2015 Pharma deals in August 2015

    Collaboration. 219. Relypsa. Vifor Fresenius. Patiromer oral suspension in treating hyperkalemia.

  • Pharma deals during November 2013 Pharma deals during November 2013

    Relypsa, a late-stage biotech developing a phase III treatment for hyperkalemia, get its IPO away but at a significantly reduced price (from a range of $16 to $19 per share

  • Pharma deals during October 2013 Pharma deals during October 2013

    Examples of recent IPOS. Company. Product/technology. Target ($m). Relypsa. Patiromer for hyperkalaemia in chronic kidney disease (phase III).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • OPKO appoints vice president of medical affairs OPKO appoints vice president of medical affairs

    Dr Douglass Laidlaw brings experience from Relypsa and Sanofi. Miami-based OPKO Health has appointed Dr Douglass Laidlaw as vice president of medical affairs. ... He previously served as Relypsa's executive director, medical affairs and Sanofi's national

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics